文献速递脑血管病认知障碍与痴呆

强化与标准血压控制对阿尔茨海默病MRI生物标志物的影响:SPRINT MIND随机试验二次分析

Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial.
PubMed 文献 · JAMA Neurol · 2021-01-01

该研究为SPRINT MIND试验的二次分析,纳入673例高血压患者,随机接受强化(收缩压<120 mm Hg)或标准(<140 mm Hg)降压治疗,中位随访3.98年。强化组海马体积下降更显著(组间差值-0.033 cm3,P=0.03),但其他AD相关MRI标志物无显著组间差异。

要点

  • 强化降压与海马体积下降更显著相关,但幅度小。
  • 其他AD相关MRI标志物(区域萎缩、脑血流、各向异性)无差异。
  • 强化降压对AD病理影像标志物的影响有限。

核心结论

  • 强化降压较标准降压与海马体积更显著下降相关,但未影响其他AD相关MRI标志物。

研究设计与样本

  • SPRINT MIND试验的二次分析,多中心随机对照,纳入673例50岁以上高血压患者,基线MRI后中位3.98年随访。

主要发现

  • 强化组海马体积从7.45 cm3降至7.39 cm3(差值-0.06 cm3,95%CI -0.08至-0.04),标准组从7.48 cm3降至7.46 cm3(差值-0.02 cm3,95%CI -0.05至-0.003)。
  • 组间海马体积变化差值为-0.033 cm3(95%CI -0.062至-0.003;P=0.03)。
  • AD区域萎缩、脑血流及扣带回各向异性均无显著组间差异。

关键数值与推荐

  • 强化降压目标为收缩压<120 mm Hg,标准降压目标为<140 mm Hg。

临床怎么用

  • 强化降压对AD影像标志物的影响有限,不应以此作为强化降压预防AD的依据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Meta-analyses of randomized clinical trials have indicated that improved hypertension control reduces the risk for cognitive impairment and dementia. However, it is unclear to what extent pathways reflective of Alzheimer disease (AD) pathology are affected by hypertension control. OBJECTIVE: To evaluate the association of intensive blood pressure control on AD-related brain biomarkers. DESIGN, SETTING, AND PARTICIPANTS: This is a substudy of the Systolic Blood Pressure Intervention Trial (SPRINT MIND), a multicenter randomized clinical trial that compared the efficacy of 2 different blood pressure-lowering strategies. Potential participants (n = 1267) 50 years or older with hypertension and without a history of diabetes or stroke were approached for a brain magnetic resonance imaging (MRI) study. Of these, 205 participants were deemed ineligible and 269 did not agree to participate; 673 and 454 participants completed brain MRI at baseline and at 4-year follow-up, respectively; the final follow-up date was July 1, 2016. Analysis began September 2019 and ended November 2020. INTERVENTIONS: Participants were randomized to either a systolic blood pressure goal of less than 120 mm Hg (intensive treatment: n = 356) or less than 140 mm Hg (standard treatment: n = 317). MAIN OUTCOMES AND MEASURES: Changes in hippocampal volume, measures of AD regional atrophy, posterior cingulate cerebral blood flow, and mean fractional anisotropy in the cingulum bundle. RESULTS: Among 673 recruited patients who had baseline MRI (mean [SD] age, 67.3 [8.2] years; 271 women [40.3%]), 454 completed the follow-up MRI at a median (interquartile range) of 3.98 (3.7-4.1) years after randomization. In the intensive treatment group, mean hippocampal volume decreased from 7.45 cm3 to 7.39 cm3 (difference, -0.06 cm3; 95% CI, -0.08 to -0.04) vs a decrease from 7.48 cm3 to 7.46 cm3 (difference, -0.02 cm3; 95% CI, -0.05 to -0.003) in the standard treatment group (between-group difference in change, -0.033 cm3; 95% CI, -0.062 to -0.003; P = .03). There were no significant treatment group differences for measures of AD regional atrophy, cerebral blood flow, or mean fractional anisotropy. CONCLUSIONS AND RELEVANCE: Intensive treatment was associated with a small but statistically significant greater decrease in hippocampal volume compared with standard treatment, consistent with the observation that intensive treatment is associated with greater decreases in total brain volume. However, intensive treatment was not associated with changes in any of the other MRI biomarkers of AD compared with standard treatment. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT01206062.

来源:JAMA Neurol,查看原文。版权归原作者所有。

引用

  1. Nasrallah IM, Gaussoin SA, Pomponio R, et al. Association of Intensive vs Standard Blood Pressure Control With Magnetic Resonance Imaging Biomarkers of Alzheimer Disease: Secondary Analysis of the SPRINT MIND Randomized Trial. JAMA Neurol. 2021. PMID: 33683313. doi:10.1001/jamaneurol.2021.0178

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。